RCKT · Rocket Pharmaceuticals, Inc.

Rocket’s sale of its Rare Pediatric Disease Priority Review Voucher represents a high-materiality strategic capital event. The $180 million non-dilutive proceeds directly address near-term liquidity needs while reinforcing financial discipline — a critical consideration for a clinical-stage biotechnology company with multiple late-phase cardiovascular programs. The PRV’s origin ties directly to the FDA’s accelerated approval of KRESLADI™, underscoring the value of regulatory milestones as monetizable assets under the reauthorized PRV program (extended in February 2026). Management explicitly links the proceeds to advancing three prioritized clinical-stage cardiovascular gene therapies — Danon disease, PKP2-associated arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy — each targeting major inherited cardiomyopathy subtypes with significant unmet need. The stated extension of the cash runway into Q2 2028 provides visibility through key upcoming clinical milestones, reducing near-term financing risk. Importantly, the transaction is not contingent on regulatory approvals beyond standard antitrust clearance, and closing is expected without material delay. While forward-looking statements caution that cash runway projections are subject to change, the $180 million figure is contractually fixed and unconditional upon performance, making it a highly reliable near-term cash inflow. This monetization reflects a deliberate portfolio optimization strategy, shifting focus from hematology (KRESLADI™’s indication) toward cardiovascular indications where Rocket has built proprietary AAV manufacturing capabilities and multi-year cardiac safety data — positioning the company to execute on a focused, capital-efficient development path.